Welcome to our dedicated page for ANBIO BIOTECHNOLOGY SEC filings (Ticker: NNNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anbio Biotechnology (NNNN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Global Market. Anbio files with the U.S. Securities and Exchange Commission in connection with its initial public offering and ongoing reporting obligations related to its global in vitro diagnostics business.
Investors can review Anbio’s registration statement on Form F-1, which describes its offering of Class A ordinary shares, intended use of proceeds for expanding its sales and distribution network, research and development, and working capital and general corporate purposes. Subsequent current reports on Form 6-K supply updates on significant corporate events. For example, a Form 6-K details the termination of YCM CPA INC. as Anbio’s independent registered public accounting firm and the appointment of HTL International, LLC, along with disclosures that there were no disagreements or reportable events as defined under Regulation S-K.
Through this page, users can monitor Anbio’s periodic and current reports to understand how it presents its IVD platforms, global operations and risk factors in official filings. Stock Titan enhances these documents with AI-powered summaries that explain key sections, helping readers interpret complex accounting, auditing and disclosure language. As new filings are posted to the SEC’s EDGAR system, they are made available here with structured access to exhibits and narrative sections.
In addition to registration and current reports, this page can be used to track future annual reports on Form 20-F, interim updates on Form 6-K and other relevant submissions, offering a centralized view of Anbio’s regulatory reporting history and governance developments.
Anbio Biotechnology reported a change in its independent registered public accounting firm. On February 11, 2026, the Board of Directors and Audit Committee approved and ratified the appointment of GGF CPA LTD to audit the company’s financial statements, effective the same date. The report states that during the two most recent fiscal years ended December 31, 2025 and 2024, and subsequent interim periods before this engagement, neither the company nor anyone on its behalf consulted GGF CPA LTD. A letter from the former auditor, HTL International, LLC, addressed to the U.S. Securities and Exchange Commission is included as Exhibit 16.1.
Anbio Biotechnology has appointed Michael Zhang as a director, Chair of the Audit Committee, and member of the Nominating and Compensation Committees, effective January 21, 2026. He replaces Kenneth Li, whose departure was not due to any disagreement with the company’s operations, policies, or procedures.
Zhang has over 30 years of finance experience and has been a managing partner at Healthcare Alpha Management since 2014. The board determined he is independent under Nasdaq rules and qualifies as an “audit committee financial expert.” Under his offer letter, he will serve until a successor is elected and qualified and will receive US$30,000 per calendar year, payable on a semiannual basis.
Anbio Biotechnology changed its independent registered public accounting firm. The Board of Directors and Audit Committee approved and ratified the appointment of HTL International, LLC as the new auditor, effective November 10, 2025.
The report also references Exhibit 16.1, a letter from YCM CPA INC. addressed to the U.S. Securities and Exchange Commission. This update focuses on auditor succession and related administrative matters under a Form 6-K.